Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fulcrum Therapeutics Inc
(NQ:
FULC
)
9.240
-0.450 (-4.64%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Fulcrum Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
July 31, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
July 24, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 4/12
April 12, 2024
Via
Investor Brand Network
Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 3/6
March 06, 2024
Via
Investor Brand Network
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
June 12, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
June 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate in Upcoming May Conferences
May 09, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
May 08, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
May 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
March 28, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
March 18, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
February 27, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
February 20, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
November 09, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Inc. (NASDAQ: FULC) Near the Top of Equities by Percentage Gain on 11/7
November 07, 2023
Via
Investor Brand Network
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
November 07, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
October 31, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
September 22, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 15, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ:FULC Long Term Investor Alert: Investigation of Potential Wrongdoing at Fulcrum Therapeutics, Inc.
September 14, 2023
San Diego, CA -- (SBWIRE) -- 09/14/2023 -- Certain directors of Fulcrum Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties.
Via
SBWire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
September 13, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food...
Via
FinancialNewsMedia
Exposures
Product Safety
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.